Mechanism and regulation of V(D)J repair
V(D)J修复机制及调控
基本信息
- 批准号:8075422
- 负责人:
- 金额:$ 32.46万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-06-15 至 2014-05-31
- 项目状态:已结题
- 来源:
- 关键词:AffectAgeAmino AcidsAntibodiesAntigensB-LymphocytesCellsCleaved cellComplexCryoelectron MicroscopyCrystallizationCytoplasmDNADNA Binding DomainDNA RepairDNA-PKcsDataData SetDefectDevelopmentDiseaseG22P1 geneGelGenesGenetic RecombinationGenome StabilityGenomicsGrowthHealthHumanImmuneImmune systemImmunodeficiency and CancerImmunologic Deficiency SyndromesIn VitroKnowledgeLIG4 geneLigaseLinkLymphocyteLymphoidMediatingMicrocephalyMolecularMutationN-terminalNonhomologous DNA End JoiningPaste substancePathway interactionsPatientsPatternPeptide Signal SequencesPhenotypePlayPost-Translational Protein ProcessingPrincipal InvestigatorProcessPropertyProtein FragmentProteinsRAG1 geneRecombinant ProteinsRegulationRoleSpecificityStem cellsStructureSyndromeT-Cell ReceptorT-LymphocyteV(D)J RecombinationWorkXRCC4 geneartemisbasecomplex IVexhaustionhuman diseasein vivomigrationmutantneural growthneurodevelopmentnovelprogramsprotein complexprotein protein interactionrecombinational repairrepairedresearch study
项目摘要
DESCRIPTION (provided by applicant): Ligase IV has been shown to play critical roles in Non-Homologous End Joining (NHEJ), V(D)J recombination and development of the immune system, stem cell exhaustion, ageing and neural growth and development, as exemplified by the phenotype of patients with hypomorphic mutations in Ligase IV. Numerous proteins have been shown to modulate Ligase IV activity. Among them, XRCC4 and Cernunnos/XLF are perhaps the best/most conclusively characterized. Both of these factors, like Ligase IV, are part of the core-NHEJ machinery. Human mutations in XRCC4 have not been described yet, but interestingly, Cernunnos/XLF mutations in humans result in growth defects, microcephaly and immunodeficiency, similar to what has been observed for Ligase IV mutations. Our recent findings have identified Artemis, a factor also linked to immunodeficiency in humans, as a protein that directly interacts with Ligase IV, in addition we have observed regulation of XRCC4 by Ligase IV. In this project we propose to analyze the functional relevance of these novel Ligase IV/Artemis complex in genomic stability and V(D)J recombination. The mechanism by which Ligase IV regulates XRCC4 function, and the composition and function of endogenous Ligase IV complexes in lymphocytes will also be investigated. Our preliminary work with Ligase IV recombinant protein and protein fragments has resulted in crystallization of a Ligase IV fragment containing the Ligase IV DNA binding domain. Experiments are proposed to solve the structure of Ligase IV and/or Ligase IV in complex with Artemis. All these are challenging yet very relevant experiments for which we show significant progresses. Furthermore, the impact of mutations identified in patients with LIG4 syndrome on regulation of its function by Artemis and on how these mutant Ligase IV proteins affect XRCC4 function will also be investigated. Information gained from the proposed studies will contribute to a molecular and structural understanding of NHEJ, V(D)J recombination and human diseases linked to defects in both of these processes. PUBLIC HEALTH RELEVANCE: Despite important progress in our understanding of Ligase IV function, its structure remains largely uncharacterized and our preliminary data suggest novel mechanisms of regulation that remain to be unraveled. This project proposes to investigate our preliminary finding on novel Ligase IV interactions and functions by using in vivo and in vitro approaches; we also propose studies to solve the structure of Ligase IV and Ligase IV complexes. By increasing our knowledge of Ligase IV structure, function and regulation, in V(D)J recombination and DNA repair, the proposed work will contribute to our understanding of human disease, specifically, Ligase IV and Artemis mediated, immunodeficiency and cancer and will facilitate the path to find better treatments for this debilitating diseases.
描述(由申请人提供):已显示连接酶IV在非同源末端连接(NHEJ),V(d)J的重组和发育,免疫系统的重组和发育,干细胞衰竭,衰老和神经生长和发育的重组和发育中起关键作用,这是由患者iiv患者表现出的表型的概念。已显示许多蛋白质可以调节连接酶IV活性。其中,XRCC4和Cernunnos/XLF也许是最好/最终的特征。这两个因素(例如连接酶IV)都是核心NHEJ机械的一部分。 XRCC4中的人类突变尚未被描述,但有趣的是,人类中的Cernunnos/XLF突变导致生长缺陷,小头畸形和免疫缺陷,类似于连接酶IV突变的人类。我们最近的发现已经确定了Artemis,这也是与人类免疫缺陷有关的因素,作为一种直接与连接酶IV相互作用的蛋白质,此外,我们还观察到了连接酶IV对XRCC4的调节。在这个项目中,我们建议分析这些新型连接酶IV/Artemis复合物在基因组稳定性和V(d)J重组中的功能相关性。连接酶IV调节XRCC4功能的机制以及内源性连接酶IV酶在淋巴细胞中的组成和功能也将进行研究。我们与连接酶IV重组蛋白和蛋白质片段的初步工作导致结晶的连接酶IV片段含有连接酶IV DNA结合结构域。提出了实验来解决与Artemis复合物中连接酶IV和/或连接酶IV的结构。所有这些都是充满挑战但非常相关的实验,我们表现出了重大进展。此外,还将研究在Lig4综合征患者中鉴定出的突变对Artemis调节其功能以及这些突变型连接酶IV蛋白如何影响XRCC4功能的影响。从拟议的研究中获得的信息将有助于对NHEJ,V(d)J重组和与缺陷相关的NHEJ,V(d)J重组和人类疾病的分子和结构性理解。公共卫生相关性:尽管我们对连接酶IV功能的理解取得了重要成就,但其结构仍然没有表征,我们的初步数据表明,调节的新型机制尚未阐明。该项目建议通过使用体内和体外方法来研究我们对新型连接酶IV相互作用和功能的初步发现。我们还提出了解决连接酶IV和连接酶IV复合物的结构的研究。通过提高我们对连接酶IV结构,功能和调节的了解,在V(d)J重组和DNA修复中,提出的工作将有助于我们对人类疾病的理解,特别是连接酶IV和Artemis介导的免疫缺陷和癌症,并将促进为这种衰弱疾病找到更好治疗的途径。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
PATRICIA CORTES其他文献
PATRICIA CORTES的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('PATRICIA CORTES', 18)}}的其他基金
Regulation of V(D)J recombination by Rag2 C terminus
Rag2 C 末端对 V(D)J 重组的调节
- 批准号:
8073125 - 财政年份:2010
- 资助金额:
$ 32.46万 - 项目类别:
Regulation of V(D)J recombination by Rag2 C terminus
Rag2 C 末端对 V(D)J 重组的调节
- 批准号:
7781189 - 财政年份:2010
- 资助金额:
$ 32.46万 - 项目类别:
Regulation of V(D)J recombination by Rag2 C terminus
Rag2 C 末端对 V(D)J 重组的调节
- 批准号:
8260320 - 财政年份:2010
- 资助金额:
$ 32.46万 - 项目类别:
Regulation of V(D)J recombination by Rag2 C terminus
Rag2 C 末端对 V(D)J 重组的调节
- 批准号:
8653520 - 财政年份:2010
- 资助金额:
$ 32.46万 - 项目类别:
Regulation of V(D)J recombination by Rag2 C terminus
Rag2 C 末端对 V(D)J 重组的调节
- 批准号:
8458581 - 财政年份:2010
- 资助金额:
$ 32.46万 - 项目类别:
Artemis: Biochemical ,structural and functional analysis
Artemis:生化、结构和功能分析
- 批准号:
7372935 - 财政年份:2009
- 资助金额:
$ 32.46万 - 项目类别:
Artemis: Biochemical ,structural and functional analysis
Artemis:生化、结构和功能分析
- 批准号:
7896656 - 财政年份:2009
- 资助金额:
$ 32.46万 - 项目类别:
相似国自然基金
无线供能边缘网络中基于信息年龄的能量与数据协同调度算法研究
- 批准号:62372118
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
CHCHD2在年龄相关肝脏胆固醇代谢紊乱中的作用及机制
- 批准号:82300679
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
颗粒细胞棕榈酰化蛋白FXR1靶向CX43mRNA在年龄相关卵母细胞质量下降中的机制研究
- 批准号:82301784
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
年龄相关性黄斑变性治疗中双靶向药物递释策略及其机制研究
- 批准号:82301217
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
多氯联苯与机体交互作用对生物学年龄的影响及在衰老中的作用机制
- 批准号:82373667
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
相似海外基金
Role of mitochondrial GDAP1 in Alzheimer's disease
线粒体 GDAP1 在阿尔茨海默病中的作用
- 批准号:
10739858 - 财政年份:2023
- 资助金额:
$ 32.46万 - 项目类别:
Dissecting connections between diet, the microbiome and Alzheimers disease
剖析饮食、微生物组和阿尔茨海默病之间的联系
- 批准号:
10740056 - 财政年份:2023
- 资助金额:
$ 32.46万 - 项目类别:
The regulation of cancer and aging by methionine
蛋氨酸对癌症和衰老的调节
- 批准号:
10750559 - 财政年份:2023
- 资助金额:
$ 32.46万 - 项目类别:
Mechanisms of mitochondrial-ER communication during dietary and thermal induced stress
饮食和热应激期间线粒体-内质网通讯的机制
- 批准号:
10663603 - 财政年份:2023
- 资助金额:
$ 32.46万 - 项目类别:
Regulation of cellular senescence and metabolic health by dietary protein
膳食蛋白质调节细胞衰老和代谢健康
- 批准号:
10678729 - 财政年份:2023
- 资助金额:
$ 32.46万 - 项目类别: